383 related articles for article (PubMed ID: 30222141)
1. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.
Zalenskaya IA; Chandra N; Yousefieh N; Fang X; Adedipe OE; Jackson SS; Anderson SM; Mauck CK; Schwartz JL; Thurman AR; Doncel GF
J Clin Invest; 2018 Oct; 128(10):4622-4638. PubMed ID: 30222141
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition.
Thurman A; Chandra N; Schwartz JL; Brache V; Chen BA; Asin S; Rollenhagen C; Herold BC; Fichorova RN; Hillier SL; Weiner DH; Mauck C; Doncel GF
AIDS Res Hum Retroviruses; 2019 Sep; 35(9):853-864. PubMed ID: 30997816
[TBL] [Abstract][Full Text] [Related]
3. Research gaps in defining the biological link between HIV risk and hormonal contraception.
Murphy K; Irvin SC; Herold BC
Am J Reprod Immunol; 2014 Aug; 72(2):228-35. PubMed ID: 24548147
[TBL] [Abstract][Full Text] [Related]
4. Increased Cervical CD4
Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
[TBL] [Abstract][Full Text] [Related]
5. Progestin-based contraception regimens modulate expression of putative HIV risk factors in the vaginal epithelium of pig-tailed Macaques.
Bosinger SE; Tharp GK; Patel NB; Zhao C; Payne TL; Dietz Ostergaard S; Butler K; Ellis S; Johnson RL; Kersh EN; McNicholl JM; Vishwanathan SA
Am J Reprod Immunol; 2018 Oct; 80(4):e13029. PubMed ID: 30076667
[TBL] [Abstract][Full Text] [Related]
6. Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
Birse KD; Romas LM; Guthrie BL; Nilsson P; Bosire R; Kiarie J; Farquhar C; Broliden K; Burgener AD
J Infect Dis; 2017 Feb; 215(4):590-598. PubMed ID: 28011908
[TBL] [Abstract][Full Text] [Related]
7. Depot Medroxyprogesterone Acetate Use Is Associated With Elevated Innate Immune Effector Molecules in Cervicovaginal Secretions of HIV-1-Uninfected Women.
Guthrie BL; Introini A; Roxby AC; Choi RY; Bosire R; Lohman-Payne B; Hirbod T; Farquhar C; Broliden K
J Acquir Immune Defic Syndr; 2015 May; 69(1):1-10. PubMed ID: 25622059
[TBL] [Abstract][Full Text] [Related]
8. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate.
Bradley F; Franzén Boger M; Kaldhusdal V; Åhlberg A; Edfeldt G; Lajoie J; Bergström S; Omollo K; Damdimopoulos A; Czarnewski P; Månberg A; Oyugi J; Kimani J; Nilsson P; Fowke K; Tjernlund A; Broliden K
PLoS Pathog; 2022 May; 18(5):e1010494. PubMed ID: 35533147
[TBL] [Abstract][Full Text] [Related]
10. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
[TBL] [Abstract][Full Text] [Related]
11. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
12. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.
Morrison CS; Chen PL; Kwok C; Baeten JM; Brown J; Crook AM; Van Damme L; Delany-Moretlwe S; Francis SC; Friedland BA; Hayes RJ; Heffron R; Kapiga S; Karim QA; Karpoff S; Kaul R; McClelland RS; McCormack S; McGrath N; Myer L; Rees H; van der Straten A; Watson-Jones D; van de Wijgert JH; Stalter R; Low N
PLoS Med; 2015 Jan; 12(1):e1001778. PubMed ID: 25612136
[TBL] [Abstract][Full Text] [Related]
13. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
Jain AK
Contraception; 2012 Dec; 86(6):645-52. PubMed ID: 22541635
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
15. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.
Grabowski MK; Gray RH; Makumbi F; Kagaayi J; Redd AD; Kigozi G; Reynolds SJ; Nalugoda F; Lutalo T; Wawer MJ; Serwadda D; Quinn TC; Tobian AAR
Lancet Glob Health; 2015 Aug; 3(8):e478-e486. PubMed ID: 26094162
[TBL] [Abstract][Full Text] [Related]
16. Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada.
Socías ME; Duff P; Shoveller J; Montaner JSG; Nguyen P; Ogilvie G; Shannon K
Sex Transm Infect; 2017 Jun; 93(4):284-289. PubMed ID: 27821613
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women.
Yang L; Hao Y; Hu J; Kelly D; Li H; Brown S; Tasker C; Roche NE; Chang TL; Pei Z
Emerg Microbes Infect; 2019; 8(1):197-210. PubMed ID: 30866773
[TBL] [Abstract][Full Text] [Related]
18. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
19. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques.
Radzio J; Hanley K; Mitchell J; Ellis S; Deyounks F; Jenkins LT; Hanson D; Heneine W; García-Lerma JG
AIDS; 2014 Jun; 28(10):1431-9. PubMed ID: 24759208
[TBL] [Abstract][Full Text] [Related]
20. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
Hapgood JP
AIDS Res Hum Retroviruses; 2020 May; 36(5):357-366. PubMed ID: 31797677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
